NOBO Medicine
Biopharmaceutical and translational research organization focused on precision medicines and research into age-related immune dysfunction (clonal hematopoiesis). Integrates biomarker, genomic, imaging, and clinical cohort data to prioritize therapeutic candidates and guide clinical development for hematologic malignancies, chronic inflammatory diseases, and related cardiovascular and neurodegenerative conditions. Produces peer-reviewed translational and clinical publications and operates clinical-stage oncology programs alongside development of machine‑learning diagnostic tools.
Industries
N/A
Nr. of Employees
small (1-50)
NOBO Medicine
Sejong Tower 613, 126 Achasan‑ro, Seongdong‑gu, Seoul (04783), South Korea; Fax 02-6215-6205
Patents
Products
Clinical‑stage BTK/TEC pathway inhibitor programs
Clinical programs developing BTK/TEC pathway small‑molecule inhibitors for relapsed/refractory central nervous system and systemic B‑cell lymphomas, evaluated in combination regimens.
Preclinical small‑molecule hemato‑inflammation programs
Early discovery programs targeting inflammatory and myeloproliferative mechanisms including caspase and JAK2 pathway inhibitors.
Machine‑learning clinical decision support tool for TMA
An ensemble ML model and web‑based nomogram validated for differential diagnosis of thrombotic microangiopathy using multicenter clinical datasets.
Clinical‑stage BTK/TEC pathway inhibitor programs
Clinical programs developing BTK/TEC pathway small‑molecule inhibitors for relapsed/refractory central nervous system and systemic B‑cell lymphomas, evaluated in combination regimens.
Preclinical small‑molecule hemato‑inflammation programs
Early discovery programs targeting inflammatory and myeloproliferative mechanisms including caspase and JAK2 pathway inhibitors.
Machine‑learning clinical decision support tool for TMA
An ensemble ML model and web‑based nomogram validated for differential diagnosis of thrombotic microangiopathy using multicenter clinical datasets.
Services
Design and conduct of multicenter clinical studies including IND preparation and Phase I/II execution.
Genomic sequencing analysis, biomarker selection, and translational study analytics to inform development decisions and publications.
Support for regulatory filings, orphan designation processes, and partnership negotiations for technology transfer.
Design and analysis services for observational cohorts, sequencing studies, imaging biomarker integration, and manuscript preparation for peer‑reviewed journals.
Design and conduct of multicenter clinical studies including IND preparation and Phase I/II execution.
Genomic sequencing analysis, biomarker selection, and translational study analytics to inform development decisions and publications.
Support for regulatory filings, orphan designation processes, and partnership negotiations for technology transfer.
Design and analysis services for observational cohorts, sequencing studies, imaging biomarker integration, and manuscript preparation for peer‑reviewed journals.
Expertise Areas
- Precision medicine and translational platform development
- Clonal hematopoiesis and hematologic‑cardio‑neuro translational research
- Oncology drug development and early‑phase clinical trials
- Biomarker discovery, validation, and imaging biomarker integration
Key Technologies
- Targeted deep sequencing (high‑depth panels)
- Linked‑read sequencing for haplotyping
- Next‑generation sequencing (NGS) analysis pipelines
- Ensemble machine learning and predictive classifiers
News & Updates
Interim Phase II results reported high response rates in relapsed/refractory DLBCL and primary CNS lymphoma presented at an international lymphoma meeting.
Selection of a BTK/TEC inhibitor program for KDDF support to advance multi‑center Phase II clinical studies.
Regulatory authority granted orphan/rare‑disease designation for a CNS lymphoma development candidate.
Progression from co‑development to a technology transfer/licensing step with an external pharmaceutical partner.
Regulatory approval received to start a Phase II multicenter clinical study for relapsed/refractory central nervous system lymphoma.
Association of clonal hematopoiesis with myocardial tissue differences in non‑ischemic heart failure
Study linking presence of clonal hematopoiesis to higher cardiac MRI mapping values and late gadolinium enhancement in non‑ischemic heart failure patients.
Interim Phase II results reported high response rates in relapsed/refractory DLBCL and primary CNS lymphoma presented at an international lymphoma meeting.
Selection of a BTK/TEC inhibitor program for KDDF support to advance multi‑center Phase II clinical studies.
Regulatory authority granted orphan/rare‑disease designation for a CNS lymphoma development candidate.
Progression from co‑development to a technology transfer/licensing step with an external pharmaceutical partner.
Regulatory approval received to start a Phase II multicenter clinical study for relapsed/refractory central nervous system lymphoma.
Association of clonal hematopoiesis with myocardial tissue differences in non‑ischemic heart failure
Study linking presence of clonal hematopoiesis to higher cardiac MRI mapping values and late gadolinium enhancement in non‑ischemic heart failure patients.